Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients

E Guttman‐Yassky, Y Renert‐Yuval, J Bares… - Allergy, 2022 - Wiley Online Library
Background Treatments for alopecia areata (AA) patients with extensive scalp hair loss are
limited, and recent evidence supports a role for type 2 T‐cell (Th2)‐immune response in AA …
被引用次数：74 相关文章

Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients

E Guttman-Yassky, Y Renert-Yuval, J Bares… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Treatments for alopecia areata (AA) patients with extensive scalp hair loss are
limited, and recent evidence supports a role for type 2 T-cell (Th2)-immune response in AA …
[HTML] nih.gov

[HTML][HTML] Phase 2a Randomized Clinical Trial of Dupilumab (anti-IL-4Rα) for Alopecia Areata Patients

E Guttman-Yassky, Y Renert-Yuval, J Bares, M Chima… - Allergy, 2022 - ncbi.nlm.nih.gov
Background Treatments for alopecia areata (AA) patients with extensive scalp hair loss are
limited, and recent evidence supports a role for type 2 T-cell (Th2)-immune response in AA …

Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.

E Guttman-Yassky, Y Renert-Yuval, J Bares, M Chima… - Allergy, 2021 - europepmc.org
Background Treatments for alopecia areata (AA) patients with extensive scalp hair loss are
limited, and recent evidence supports a role for type 2 T-cell (Th2)-immune response in AA …

Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients.

E Guttman‐Yassky, Y Renert‐Yuval, J Bares… - Allergy, 2022 - search.ebscohost.com
Background: Treatments for alopecia areata (AA) patients with extensive scalp hair loss are
limited, and recent evidence supports a role for type 2 T‐cell (Th2)‐immune response in AA …

Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients

E Guttman‐Yassky, Y Renert‐Yuval, J Bares, M Chima… - Allergy, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited, and …

Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.

E Guttman-Yassky, Y Renert-Yuval, J Bares, M Chima… - Allergy, 2021 - europepmc.org
Background Treatments for alopecia areata (AA) patients with extensive scalp hair loss are
limited, and recent evidence supports a role for type 2 T-cell (Th2)-immune response in AA …